In the trial, inhaled Ampion will be used to treat patients with respiratory distress associated with Covid-19.
Leading regenerative medicine advocacy group leverages GlobalData’s datasets to highlight a record year
The Alliance for Regenerative Medicine’s report reveals the data behind a “year of firsts and records” for the sector.
Yselty offers promise in the endometriosis market because of its ability to alleviate pain while minimising other adverse effects.
Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said.
The firms may struggle to convince regulators that their HIF PHIs don't share roxadustat’s safety concerns in CKD.